The price you pay for Treanda may depend on factors such as the form you take, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...
Treanda (bendamustine) can cause side effects that range from mild to serious. More common side effects include nausea, vomiting, and fatigue. If side effects from Treanda become difficult to tolerate ...
NEW YORK, Dec 9 (Reuters) - Cephalon Inc's experimental cancer drug Treanda was significantly more effective than a common chemotherapy agent in helping patients with chronic lymphocytic leukemia (CLL ...
The combination regimen demonstrated improved efficacy outcomes with a tolerable profile among patients with relapsed/refractory mantle cell lymphoma. As the treatment landscape continues to grow in ...
The approval of the liquid formulation will improve convenience of use for healthcare professionals. Earlier, healthcare professionals had to reconstitute the lyophilized powder with sterile water ...
Treanda (bendamustine) may be an effective substitute for CHOP as the chemotherapy partner to Rituxan (rituximab) for patients receiving initial therapy for advanced follicular or mantle cell ...
Cephalon could have a blockbuster on its hands following the release of new data about its tumor-fighting therapy Treanda. The drug is currently approved for a form of non-Hodgkin lymphoma, which ...
The TREANDA NDA for relapsed indolent NHL is supported by three studies in patients with NHL, including one in combination with rituximab. In these studies, patients treated with TREANDA had a high ...
FRAZER, Pa., March 20 Cephalon, Inc.(Nasdaq: CEPH) today announced that the U.S. Food and Drug Administration(FDA) has approved TREANDA(R) (bendamustine hydrochloride) for Injection forthe treatment ...
Cephalon has received another query from the feds. As Pharmalot reports, the company disclosed a subpoena from the U.S. Attorney's Office in New York, requesting information about the company's ...
FRAZER, Pa., Sept. 21 Cephalon, Inc.(Nasdaq: CEPH) today announced that it has submitted a New Drug Application(NDA) to the U.S. Food and Drug Administration (FDA) requesting approval ofTREANDA(R) ...
The FDA has approved Cephalon’s Treanda (bendamustine HCl injection) for the treatment of chronic lymphocytic leukemia (CLL). Treanda is believed to induce apoptosis and mitotic catastrophe in CLL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results